The advocacy group I AM ALS secured $313 million in federal funding for its campaign to accelerate research and expand access to treatment.

ALS Canada and Brain Canada have awarded $515,000 to four early-career researchers to advance ALS research and clinical care ...

As many state legislatures across the country begin their 2026 sessions, the ALS Association released its annual ALS State Policy Report Cards, evaluating how all 50 states and Washington, D.C. are ...

Historically, people with amyotrophic lateral sclerosis (ALS) experience a relentless decline in neurological function that eventually robs them of the ability to move, speak, eat or breathe. Now, ...

Immune cells in the brain that go rogue contribute to the death of neurons, so getting rid of them may slow the progression of neurodegenerative conditions like amyotrophic lateral sclerosis ...

FAYETTEVILLE -- Even before Thursday's ceremonial ribbon-cutting for the new ALS Clinic at University of Arkansas for Medical Sciences Northwest Hospital, officials and representatives of the ALS ...

The MarketWatch News Department was not involved in the creation of this content. This funding was awarded through the ALS Association's Hoffman ALS Clinical Trial Awards Program, which aims to ...

ALS is a debilitating paralytic disease characterized by the death of upper and lower motor neurons. Fortunately, ALS is relatively rare, with an incidence rate of 1.6 per 100,000 adults, resulting in ...

Rickey Malloy (left), who receives tofersen treatment for SOD1-ALS at WashU Medicine, plays a round of golf with his wife, Jenny, and their son, Kash. Long-term use of tofersen, a new drug approved by ...